Abstract
Introduction: Recent studies showed that insulin-like growth factor-1 (IGF-1) and either erythropoietin (EPO) or the long-acting EPO analogue Darbepoetin alpha (DA) protects the heart against ischemia/reperfusion (I/R) and myocardial infarction (MI). Hypothesis: The present study examined the cardioprotective effect of simultaneous treatments with IGF-1 and DA in these models. Methods: Male adult rats were subjected to 30 minutes ischemia and 72 hours reperfusion (I/R) or 4 weeks of ischemia alone (permanent coronary occlusion; MI).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
